Publications

5063 Results

Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)

Authors
S Kopetz;K Guthrie;V Morris;H-J Lenz;A Magliocco;D Maru;S Airhart;Y Yan;R Lanman;G Manyam;D Hong;A Sorokin;C Atreya;C Allegra;K Raghav;S Wang;C Lieu;S McDonough;P Philip;H Hochster
Journal / Conference
Journal of Clinical Oncology Feb 1;39(4):285-294
Year
2021
Research Committee(s)
Gastrointestinal
PMID
PMID33356422
PMC
PMC8462593
Study Number(s)
S1406

Bortezomib, Lenalidomide, Dexamethasone with or without Elotuzumab for Untreated, High-Risk Myeloma – Primary Analysis of the SWOG-1211 Randomized Phase II Trial

Authors
S Usmani;A Hoering;S Ailawadhi;R Sexton;B Lipe;S Hita;J Valent;M Rosenzweig;J Zonder;M Dhodapkar;N Callander;T Zimmerman;P Voorhees;B Durie;V Rajkumar;P Richardson;R Orlowski
Journal / Conference
Lancet Haematology Jan;8(1):e45-e54. doi: 10.1016/S2352-3026(20)30354-9. Epub 2020 Dec 22
Year
2021
Research Committee(s)
Myeloma
PMID
PMID33357482
Study Number(s)
S1211

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

Authors
D Conti;B Darst;EJ Saunders;X Sheng;A Chou;F Schumacher;D Albanes;C Tangen;P Goodman;IM Thompson;EA Klein;A Hsing;R Eeles;Z Kote-Jarai;C Haiman
Journal / Conference
Nature Genetics, Jan;53(1):65-75
Year
2021
Research Committee(s)
Cancer Control and Prevention
PMID
PMID33398198
PMC
PMC8148035
Study Number(s)
S0000, SWOG-9217

Identifying novel susceptibility genes for colorectal cancer risk from a transcriptome-wide association study of 125,478 subjects

Authors
X Guo;W Lin;W Wen;S Bien;C Qu;J Huyghe;G Abecasis;D Albanes;S Berndt;S Bezieu;DT Bishop;H Brenner;S Buch;A Burnett-Hartman;PT Campbell;S Castellvi Bel;AT Chan;J Chang-Claude;S Chanock;SH Cho;D Conti;A de la Chapelle;E Feskens;S Gallinger;G Giles;P Goodman;A Gsur;M Guinter;M Gunter;J Hampe;H Hampel;T Harrison;R Hayes;M Hoffmeister;MA Jenkins;E Kampman;HM Kang;T Keku;HR Kim;L Le Marchand;SC Lee;CI Lee;L Li;A Lindbom;RL Milne;V Moreno;P Newcomb;D Nickerson;K Offir;U Peters;P Pharaoh;E Platz;J Potter;G Rennert;L Sakoda;C Schafmayer;SL Schmitt;R Schoen;F Schumacher;M Slattery;YR Su;C Tangen;C Ulrich;F van Duijnhoven;B Van Guelpen;K Visvanathan;P Vodicka;L Vodickova;X Wang;E White;A Wolk;MO Woods;S Gruber;G Casey;L Hsu;W Zheng
Journal / Conference
Gastroenterology Mar;160(4):1164-1178.e6. doi: 10.1053/j.gastro.2020.08.062. Epub 2020 Oct 12.
Year
2021
Research Committee(s)
Prevention
PMID
PMID33058866
PMC
PMC7956223
Study Number(s)
S0000

Alliance trial A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas

Authors
M Katz;Q Shi;J Meyers;J Herman;M Chuong;B Wolpin;S Ahmad;R Marsh;L Schwartz;S Behr;W Frankel;E Collisson;J Leenstra;A Venook;J Meyerhardt;E O'Reilly
Journal / Conference
J Clin Oncol 39, 2021 (suppl 3; abstr 419); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), oral
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021501

Immunologic Predictors of Therapeutic Response to Neoadjuvant Therapy for Pancreatic Adenocarcinoma (PDA) in SWOG S1505

Authors
D Sohal;M Duong;R Chang;Y Xue;D Delman;I Garrido-Laguna;S Mulvihill;K Affolter;MK Washington;MS Beg;A Wang-Gillam;J Wade;N Gandhi;S Ahmad;A Lowy;EG Chiroean;K Guthrie;H Hochster;PA Philip;G Beatty
Journal / Conference
J Clin Oncol 39, 2021 (suppl 3; abstr 419); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), Poster Presentation and Poster Highlights session
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
S1505

S2001: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations

Authors
V Chung;K Guthrie;M Pishvaian;X Yu;A Lowy;EG Chiorean;M Duong;E O'Reilly;PA Philip
Journal / Conference
J Clin Oncol 39, 2021 (suppl 3; abstr TPS447); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), poster session
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
S2001

Prognostic value of tumor deposits in stage III colon cancer patients, a post hoc analysis of CALGB/SWOG 80702 phase III study

Authors
R Cohen;Q Shi;J Meyers;Z Jin;M Svrcek;C Fuchs;F Couture;P Kuebler;J Bendell;P Kumar;D Lewis;B Tan;M Bertagnolli;H Hochster;C Blanke;E O'Reilly;A Shields;J Meyerhardt
Journal / Conference
J Clin Oncol 39, 2021 (suppl 3; abstr 10); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), rapid abstract presentation (oral)
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

Discordance between central vs. local response assessments in neuroendocrine tumor (NET) patients enrolled in A021202

Authors
S Geyer;M Mahoney;T Asmis;N Hall;S Karovic;M Knopp;P Kumthekar;A Nixon;E O'Reilly;L Schwartz;J Strosberg;J Meyerhardt;M Maitland;E Bergsland
Journal / Conference
J Clin Oncol 39, 2021 (suppl 3; abstr 361); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), poster
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021202

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)

Authors
M Overman;G Yothers;S Jacobs;H Sanoff;D Cohen;K Guthrie;NL Henry;P Ganz;ES Kopetz;P Lucas;CD Blanke;N Wolmark;H Hochster;T George;SMS Rocha Lima
Journal / Conference
J Clin Oncol 39, 2021 (suppl 3; abstr TPS158); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), TIPS, poster
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/NRG-GI004